Biotech Values

[jq1234]

I am listenning to the webcast. The guy from Dana Faber gave really good overall review of prostate cancer in general. XL184 is highly promising, but there are questions that can only be answered overtime with more data.

[I am mostly interested in duration of response data, I guess have to wait until ASCO]

Here are summary of key data, compared against data from Nov2010:

Per mRECIST for lead in period:

11/2010: DCR at 12-week 71% (24/34), confirmed response 9% (3/34)
02/2011: DCR at 12-week 74% (74/100), confirmed response 6% (6/100)

Per Bone scan:

11/2010: Partial or complete resolution 95% (19/20)
02/2011: Partial or complete resolution 85% (53/62)